MX2012000541A - Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos. - Google Patents

Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos.

Info

Publication number
MX2012000541A
MX2012000541A MX2012000541A MX2012000541A MX2012000541A MX 2012000541 A MX2012000541 A MX 2012000541A MX 2012000541 A MX2012000541 A MX 2012000541A MX 2012000541 A MX2012000541 A MX 2012000541A MX 2012000541 A MX2012000541 A MX 2012000541A
Authority
MX
Mexico
Prior art keywords
ans
polypeptides
nucleic acid
acid sequences
therapeutic peptides
Prior art date
Application number
MX2012000541A
Other languages
English (en)
Inventor
Richard Morgan
Hardev S Pandha
Original Assignee
Univ Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0912155.9A external-priority patent/GB0912155D0/en
Priority claimed from GBGB0921328.1A external-priority patent/GB0921328D0/en
Application filed by Univ Surrey filed Critical Univ Surrey
Publication of MX2012000541A publication Critical patent/MX2012000541A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen péptidos aislados (GLGGGDLSV, SLNESQIKI, LMLPAVLQA y FTAEQLQRL) derivados de porciones de la proteína Engrailed-2 (EN2). También se describe su uso en terapia, en particular en relación con la prevención y tratamiento de cáncer.
MX2012000541A 2009-07-13 2010-07-13 Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos. MX2012000541A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0912155.9A GB0912155D0 (en) 2009-07-13 2009-07-13 Therapeutic peptides, polypeptides and nucleic acid sequences
GBGB0921328.1A GB0921328D0 (en) 2009-12-04 2009-12-04 Therapeutic peptides, polypeptides and nucleic acid sequences
PCT/GB2010/001335 WO2011007130A1 (en) 2009-07-13 2010-07-13 Therapeutic peptides, polypeptides ans nucleic acid sequences

Publications (1)

Publication Number Publication Date
MX2012000541A true MX2012000541A (es) 2012-03-14

Family

ID=42710594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000541A MX2012000541A (es) 2009-07-13 2010-07-13 Peptidos, polipeptidos y secuencias de acidos nucleicos terapeuticos.

Country Status (12)

Country Link
US (1) US20120177672A1 (es)
EP (1) EP2454597A1 (es)
JP (1) JP2012532621A (es)
CN (1) CN102549433A (es)
AU (1) AU2010272371A1 (es)
CA (1) CA2767126A1 (es)
IL (1) IL217334A0 (es)
MX (1) MX2012000541A (es)
NZ (1) NZ597470A (es)
RU (1) RU2012100903A (es)
WO (1) WO2011007130A1 (es)
ZA (1) ZA201200046B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289929A (zh) * 2015-09-23 2018-07-17 国家科学研究中心 用于治疗神经退行性障碍的同源异型蛋白
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
EP3836951A1 (en) 2018-08-13 2021-06-23 Signablok, Inc. Peptides and compositions for targeted treatment and imaging

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312949B1 (en) * 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
US7629123B2 (en) * 2003-07-03 2009-12-08 University Of Medicine And Dentistry Of New Jersey Compositions and methods for diagnosing autism
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker

Also Published As

Publication number Publication date
JP2012532621A (ja) 2012-12-20
EP2454597A1 (en) 2012-05-23
US20120177672A1 (en) 2012-07-12
NZ597470A (en) 2013-11-29
WO2011007130A1 (en) 2011-01-20
IL217334A0 (en) 2012-02-29
CA2767126A1 (en) 2011-01-20
ZA201200046B (en) 2012-09-26
RU2012100903A (ru) 2013-08-20
AU2010272371A1 (en) 2012-02-02
CN102549433A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
WO2006081826A3 (en) Survivin peptide vaccine
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
PH12015500297A1 (en) Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
NZ599792A (en) Immunomodulatory polypeptides derived from il- 2 and their use thereof in the therapeutic of cancer and chronic infections
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MY161340A (en) Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
MY158992A (en) Forms of rifaximin and uses thereof
IN2012DN03310A (es)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
EP2759302A3 (en) 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EP2285989A4 (en) NEW TARGETS TO REGULATE ANGIOGENESIS
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
GB201001602D0 (en) Oligopeptidic compounds and uses therof
WO2012014214A3 (en) Peptides derived from plasminogen activator inhibitor-1 (pai-1) for the treatment of hypertension

Legal Events

Date Code Title Description
FA Abandonment or withdrawal